J B Chemicals & Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/c87xga5unvqd1etncj4pfm0f.pdf

Key Takeaways


Domestic Business

Chopra: "We have taken an internal aspiration that we would like to at least touch INR8 lakh productivity, which would be a good productivity for the portfolio mix that we have got."

International Formulations


Margins & Cost Structure

Khanna: "We do not want to significantly peg any number or give any guidance. But just to give you a sense that even our Ophthal portfolio, the overall margin profile will be probably higher than our standalone domestic business current margin profile as well."

Capex & Infrastructure


Guidance & Commitments

CommitmentSpecificsTimeline
Domestic revenue growth12% to 14% growth, outpacing IPM by 300–400 bpsOngoing
Volume growth vs IPMAt least 3 percentage points above IPM volume growthOngoing
Gross marginMaintain 67% to 69% rangeOngoing
EBITDA marginMaintain 27% to 29% rangeOngoing
International formulations growthHigh single-digit growthH2 FY26
US business recoveryGrowth to bounce backQ3 and Q4 FY26
CDMO full-year growthClose to 12% to 14%FY26
API quarterly run rateMaintain INR25 croreOngoing
Ophthal portfolio consolidationMargin profile higher than standalone domestic businessFrom CY27
MR field force additionOnly after productivity touches INR8 lakhNo date

Key Metrics

MetricQ2 FY26
Revenue₹1,085 cr, up 8% YoY
Domestic formulation revenue₹644 cr, up 9% YoY
International business revenue₹441 cr, up 7% YoY
CDMO revenue₹113 cr, up 20% YoY
International formulations revenue₹306 cr, up 2% YoY
API revenue₹22 cr, vs ₹19 cr in Q2 FY25
Gross margin68.2%, up 200 bps YoY from 66.2%
Operating EBITDA (excl. non-cash ESOP)₹319 cr, up 12% YoY
Operating EBITDA margin29.4%, up 100 bps YoY
Net profit₹208 cr, up 19% YoY
H1 FY26 operating cash flow₹363 cr
Net cash and equivalents (incl. mutual funds)₹939 cr as of 30 Sep 2025
Gross debt₹7 cr as of 30 Sep 2025, vs ₹14 cr on 31 Mar 2025
H1 FY26 net capex addition₹46 cr, vs ₹49 cr in H1 FY25
Domestic business volume growth4% for Q2; price growth 6%
IQVIA MAT Sep 2025 growth vs IPM12% company growth vs 8% IPM growth
MR count~2,400 active on ground
MR productivity~₹7.5 lakh
Ophthal portfolio monthly run rate~₹17–18 cr
Ophthal portfolio growth in covered markets~16%, vs market growth of ~8%
Remaining ESOP charge₹47 cr total; ₹20 cr in FY26, ₹27 cr in FY27
Full-year capex guidance~₹100 cr; maintenance capex ₹60–65 cr